VEGFA and cancer: Multimodal treatment targets multiple hallmarks concurrently because the strong selective pressure on cancer cell populations 42leads to resistance to monotherapies.43Additional multimodal therapies include dual inhibition of the mitogenic and cell cycle signalling pathways,44CDK4/6 inhibitors plus immunotherapy 45 and VEGF inhibition plus multiple classes of antimetastatic therapies,40 which, respectively, correspond to the sustained proliferative signalling, evading growth suppressors, inducing angiogenesis, and activating invasion and metastasis hallmarks of cancer.